| Name | Title | Contact Details |
|---|---|---|
G.B. Jones |
Vice President and Chief Security Officer | Profile |
Using clinical and individual behaviors, our underwriting software is able to accurately predict insurance risk. Learn more here!
e3 Solutions leads the industry in the design and implementation of enterprise carbon management software (ECM), as well as enterprise incident management (EIM) and environmental management information systems (EMIS). Serving the Fortune 500 market, educational institutions and government agencies, our mission is to design and support web-enabled software that delivers the features, benefits and business value our clients need. Our purpose is to help them achieve the integration of economic, environmental, and social responsibility they want when managing the triple bottom line (TBL). In business since 2005, with technology evolved since 1997, and staffed with a team of exceptional engineers and seasoned leaders, we possess the deep domain experience and world-class information technology expertise today's market requires.
RocketReach is the most accurate and intuitive contact discovery tool, trusted by FORTUNE 500 companies including Google, Apple, Bank of America, Morgan Stanley, just to name a few. RocketReach allows you to search over 500 million professionals, ac...
Our elite cyber security company offers network security monitoring to fortify your business and strengthen your front line.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.